40 news items
Hawaii Court Rules Against Bristol Myers, Sanofi In Blood Clot Drug Case, Increases Liability To $916M
BMY
SNY
22 May 24
.
In response to the ruling, Reuters noted that Bristol Myers and Sanofi released a joint statement expressing their disagreement
Bristol Myers Squibb Presents New 4-Year Sotyktu Data Demonstrate Durable Response Rates And Consistent Safety In Moderate-To-Severe Plaque Psoriasis
BMY
16 May 24
Following four years of continuous Sotyktu treatment, clinical response was maintained in more
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY
15 May 24
with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
overall survival (OS) across the study arms, PFS by RECIST 1.1 per BICR across the study arms, as well as objective response rate (ORR), time
npbkwz92b83d1ym9qvf679r7zme63e895ancvjg9tdcl0alfmebhi 5wz
BMY
29 Apr 24
, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights
fxhix0h9iqnzfdz rk13v46jji
BMY
26 Apr 24
', or 'Lower' their stance, it signifies their response to recent developments related to Bristol-Myers Squibb. This offers insight into analysts' perspectives
hus8xp59tyyxhe4xvoi1yizpl6t2lspuomxrx2ilwmripw
BMY
26 Apr 24
of care for decades but the durability of response to chemotherapy alone is poor and once a patient progresses, treatment options become increasingly
e715jnaby6zdxmg6pwua118ykvyje02yt2pp y4l
BMY
25 Apr 24
response
wvgd72dbg9ghg6huq0vr
AGEN
BMY
12 Apr 24
response rate (ORR) was observed after a median follow up of 13.6 months at the data cutoff of March 1, 2024.
The median duration
vojes j2w
BMY
JNJ
MRK
10 Apr 24
continues to build its heart business.
Johnson & Johnson is focusing on enhancing its cardiovascular health business in response to its
iyf49pef26i6ric9ah6zepe5gen1eya0dx4vzli7lplgdpbaql
BMY
8 Apr 24
.
With a median follow-up of 11.9 months in 94 patients, Krazati plus cetuximab demonstrated an objective response rate, the primary endpoint, of 34%, median
kovm kzpn58a56gf48v4
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
gybl 4w75orvt9hazzi6hmpkskin9wbhxcskh8zbz4dj1aa6izpp48kc
BMY
IRON
VERV
4 Apr 24
with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy. It is also indicated for the treatment